within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07D_Antipropulsives.A07DA06_Eluxadoline;

model Eluxadoline
  extends Pharmacolibrary.Drugs.ATC.A.A07DA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Eluxadoline</td></tr><tr><td>ATC code:</td><td>A07DA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist, utilized for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. It acts locally in the gastrointestinal tract, reducing bowel contractions and inhibiting pain signals. Eluxadoline is approved by regulatory agencies such as the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data based on healthy adult subjects following oral administration of eluxadoline 100 mg.</p><h4>References</h4><ol><li><p>Bonifacio, L, et al., &amp; Covington, PS (2018). Evaluation of Eluxadoline Effect on Cardiac Repolarization. <i>Clinical pharmacology in drug development</i> 7(7) 727â€“736. DOI:<a href=\"https://doi.org/10.1002/cpdd.453\">10.1002/cpdd.453</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29659201/\">https://pubmed.ncbi.nlm.nih.gov/29659201</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Eluxadoline;
